{"product_id":"generic-ivosidenib-aivodx","title":"AIVODX (Ivosidenib)","description":"\u003cp\u003eIvosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. Ivosidenib is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma.\u003csup id=\"cite_ref-Tibsovo_FDA_label_3-1\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Acute_Myeloid_Leukemia\"\u003eAcute Myeloid Leukemia\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Newly-diagnosed_acute_myeloid_leukemia_AML\"\u003eNewly-diagnosed acute myeloid leukemia (AML)\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with azacitidine or as monotherapy for newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation in adults aged ≥75 years, or who have comorbidities that preclude use of intensive induction chemotherapy\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Combination_regimen\"\u003eCombination regimen\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e500 mg PO qDay until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eFor patients without disease progression or unacceptable toxicity, continue for minimum of 6 months to allow time for clinical response\u003c\/li\u003e\n\u003cli\u003eStart ivosidenib on Cycle 1 Day 1 in combination with azacitidine 75 mg\/m\u003csup\u003e2\u003c\/sup\u003e SC\/IV qDay on Days 1-7 (or Days 1-5 and 8-9) of each 28-day cycle\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Monotherapy\"\u003eMonotherapy\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e500 mg PO qDay until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eFor patients without disease progression or unacceptable toxicity, continue for minimum of 6 months to allow time for clinical response\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Relapsed_or_refractory_AML\"\u003eRelapsed or refractory AML\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for patients with relapsed or refractory AML with a susceptible IDH1 mutation as detected by an FDA-approved test\u003c\/li\u003e\n\u003cli\u003e500 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity; treat for a minimum of 6 months to allow time for clinical response\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Cholangiocarcinoma\"\u003eCholangiocarcinoma\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for locally advanced or metastatic cholangiocarcinoma in previously treated adults with IDH1 mutation\u003c\/p\u003e\u003cp\u003e500 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797952426027,"sku":"RL2320240201730","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-03-021.jpg?v=1787022176","url":"https:\/\/xomeds.com\/products\/generic-ivosidenib-aivodx","provider":"XOMEDS","version":"1.0","type":"link"}